NCT06900088View on ClinicalTrials.gov

Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 25, 2025

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2026

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia
Interventions
DRUG

Selinexor

maintenance therapy with Selinexor combined with Azacitidine in patients with high-risk myeloid neoplasms after transplantation

Trial Locations (1)

Unknown

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China., Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER